Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward

Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward

Globally, the death rate of pancreatic ductal adenocarcinoma (PDAC) has doubled over 30 years and is likely to further increase, making PDAC a leading cause of cancer-related death in the coming years. PDAC is typically diagnosed at an advanced stage, and modified FOLFIRINOX or nab-paclitaxel and ge...

Full description

Bibliographic Details
Main Authors: Caspar Franck, Christian Müller, Rosa Rosania, Roland S. Croner, Maciej Pech, Marino Venerito
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
pancreatic ductal adenocarcinoma
palliative therapy
maintenance therapy
supportive therapy
biomarker
molecular subtypes
Online Access:https://www.mdpi.com/2072-6694/12/7/1955

Similar Items

Similar Items